Figure F-90 is titled “Change in CAPS for anticonvulsants compared with placebo.” The figure displays a forest plot reporting the weighted mean difference in CAPS scores stratified by divalproex versus placebo, tiagabine versus placebo, and topiramate versus placebo. The plot depicts a greater reduction in CAPS scores for patients treated with placebo than divalproex (1 trial, weighted mean difference 1.40, 95% CI −8.22 to 11.02). On the other hand, the plot also depicts greater reductions in CAPS scores for patients treated with tiagabine (1 trial, weighted mean difference −0.50, 95% CI −7.12 to 6.12) or topiramate (3 trials, weighted mean difference −15.53, 95% CI −19.40 to −11.65, I2=0.0%) than placebo. The overall analysis favored anticonvulsants (weighted mean difference −7.85, 95% CI −17.13 to 1.42, I2=81.4%).

Figure F-90Change in CAPS for anticonvulsants compared with placebo

Timing of outcome assessment: 8 weeks (Davis, 2008), 12 weeks (Davidson, 2007; Akuchekian, 2004; Tucker, 2007; Yeh, 2011).

From: Appendix F, Meta-Analysis

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.